



Supplementary Figure 15: MRD testing results in early stage breast cancer cohort. (A) Detection limits versus the number of SNVs tracked for each cfDNA sample. (B) Comparison of fingerprint size distributions between patients that were MRD+ at any time point and those that were always MRD-, split by distant recurrence status. The Mann-Whitney U test was used to determine whether MRD+ patients tracked significantly more mutations than MRD- patients. (C) Tumor fractions for MRD+ samples from patients with distant recurrence split by the minimum fingerprint size required to still detect MRD.